Skip to main content
. Author manuscript; available in PMC: 2011 May 1.
Published in final edited form as: Expert Opin Drug Deliv. 2010 May;7(5):631–645. doi: 10.1517/17425241003663236

Figure 7.

Figure 7

Inhibitory effects of celecoxib-PLGA microparticles on diabetes induced elevations in (A) retinal PGE2 (n = 4); (B) retinal VEGF (n =8–9); (C) vitreous-plasma protein ratio (n= 4); and (D) blood–retinal barrier leakage (n= 4). The parameters were estimated 60 days after periocular administration of the placebo or celecoxib-PLGA microparticles to rats. Data are expressed as the mean ± SD. Significantly different from the *diabetic group, the †diabetic + placebo group, or the ‡contralateral eye. Based on data from Amrite et al., 2006; Invest Ophthalmol Vis Sci 47(3): 1149-1160.